FUJIFILM: Granted iPS cell patent to the outside: Lonza Walkersville, Inc.
FUJIFILM:
FUJIFILM Cellular Dynamics:
A US subsidiary holds a patent for iPS cells.
“IPS cells for testing the safety and efficacy of drug candidate substances” are on sale.
Production of iPS cells:
There are multiple methods for producing iPS cells, but Fujifilm’s patented technology is said to be highly safe.
In addition, only a few companies / organizations can produce therapeutic iPS cells.
Until now, Fujifilm has limited “sales and patents for therapeutic iPS cells” to companies with a capital relationship.
Granted patent license:
Recently, it has decided to grant a patent license to the outside, and as the first step, it has licensed the use to a US subsidiary of Lonza.
Grant a patent for the production of therapeutic iPS cells for the development of regenerative medicine products.
Fujifilm receives license revenue from Lonza, but the amount is not disclosed.
In addition to Lonza, “inquiries have come from more than a dozen companies” (Fujifilm).
External sales of therapeutic iPS cells:
Started external sales of therapeutic iPS cells.
Regenerative medicine products using iPS cells have not been put into practical use, although clinical trials are underway for complications of blood cancer and bone marrow transplantation.
US BCC Research:
The global market for iPS cells is expected to grow from $ 2.4 billion in 2019 to $ 3.8 billion in 2024.
FUJIFILM has entered the field of regenerative medicine by applying “collagen technology cultivated in photographic film” to cell culture.
The policy is to focus on external sales of iPS cells, patent grants, and contract manufacturing.
Contract manufacturing of regenerative medicine products:
In March 2020, a therapeutic iPS cell production facility was put into operation in the United States.
In the future, we aim to become the world leader in the contract manufacturing of regenerative medicine products using iPS cells.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXMZO66135010S0A111C2XB0000/
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
FUJIFILM Cellular Dynamics and Lonza
agree to expand the availability and use of induced pluripotent stem cell technology – FUJIFILM Cellular Dynamics grants Lonza
a non-exclusive right to use their patents related to iPSC generation,
including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology –
The agreement enables drug developers
to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements MADISON, Wis., and WALKERSVILLE, Md.,
November , 2020 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer),
have entered into a worldwide agreement. The agreement enables drug developers to leverage both companies’ expertise and technologies for the generation of iPSCs through licensing agreements.
Under the agreement,
FUJIFILM Cellular Dynamics
grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for the clinical manufacture and differentiation of iPSC lines for cell therapies.
Furthermore, Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology, to enable efficient transfection of cells, stem cell and cell lines.
Cell therapies
have emerged as a promising treatment modality with the ability to augment, repair, or replace human biology, including organs, tissues and cells.
Given their incredible capacity to self-renew and the ability to become many different cell types, iPSCs are a critical material used in the development and manufacture of cell therapies.
FUJIFILM Cellular Dynamics
is a key global player with the technology and expertise in iPSC episomal generation enabling high quality, purity and reproducibility,” said Takeshi Yamamoto, chief executive officer, FUJIFILM Cellular Dynamics.
We are pleased to reach this outcome with Lonza to produce iPSC lines to better serve drug developers.
We expect to grant additional patent licenses to pharmaceutical and biotech companies to support the growth of available cell therapies.
As true leaders in our field, both companies came to an agreement which benefits our customers and brings clarity to the industry.” said Alberto Santagostino, SVP, Head of Cell and Gene Technologies, Lonza.
It shows our common goal to make high quality iPSC therapies available at affordable cost to our customers.
Additionally, we are pleased to expand the license-use of our innovative Nucleofector™ technology granted to FUJIFILM Cellular Dynamics.
This agreement further strengthens our leading end-to-end proprietary service offering for iPSCs.
In combination with Lonza’s L7™ hPSC Culture System and non-viral 4D-Nucleofector™ Transfection Technology, this represents an excellent approach for reprogramming and culturing GMP grade iPSCs”
Fujifilm Global